A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients with Essential Hypertension
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs Amlodipine/fimasartan (Primary) ; Amlodipine; Fimasartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 23 Jan 2013 Planned End Date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 14 Mar 2012 Additional lead trial investigator (Eun Seok Jeon) identified as reported by Korean Clinical Trials Register record.
- 14 Mar 2012 New source identified and integrated (KCT0000192; Clinical Research Information Service (CriS) - Republic of Korea).